🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,180 results for “Takeda Pharmaceuticals International AG” Clear

  1. SHP465 12.5mg capsules (one capsule daily)

    Takeda Pharmaceuticals International AG

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    1 trial

  2. SHP615

    Takeda Pharmaceuticals International AG

    Nervous System Diseases

    phase 3 small molecule completed

    2 trials

  3. SHP640

    Takeda Pharmaceuticals International AG

    Adenoviral Conjunctivitis

    phase 3 small molecule terminated

    2 trials

  4. SHP640

    Takeda Pharmaceuticals International AG

    Bacterial Conjunctivitis

    phase 3 small molecule completed

    1 trial

  5. SOTYKTU 6 mg film-coated tablets, Matching Placebo for Deucravacitinib, SOTYKTU 6 mg film-coated tablets, SOTYKTU 6 mg film-coated tablets, ZASOCITINIB, SOTYKTU 6 mg film-coated tablets, Matching Placebo for TAK-279

    Takeda Pharmaceuticals International AG

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  6. SPD422 (anagrelide hydrochloride)

    Takeda Pharmaceuticals International AG

    Essential Thrombocythemia (ET)

    phase 3 small molecule completed

    1 trial

  7. SPD465

    Takeda Pharmaceuticals International AG

    Attention-Deficit/Hyperactivity Disorder

    phase 3 small molecule completed

    2 trials

  8. SPD476

    Takeda Pharmaceuticals International AG

    Ulcerative Colitis

    phase 3 small molecule completed

    1 trial

  9. SPD476 (1.2g)

    Takeda Pharmaceuticals International AG

    Diverticulitis

    phase 3 small molecule completed

    1 trial

  10. SPD476 (mesalazine)

    Takeda Pharmaceuticals International AG

    Colitis, Ulcerative

    phase 3 small molecule completed

    1 trial

  11. SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine

    Takeda Pharmaceuticals International AG

    Ulcerative Colitis

    phase 3 small molecule completed

    1 trial

  12. SPD476, MMX™ mesalazine, 1.2g extended release tablet

    Takeda Pharmaceuticals International AG

    Diverticulitis

    phase 3 small molecule completed

    1 trial

  13. SPD489

    Takeda Pharmaceuticals International AG

    ADHD

    phase 3 small molecule terminated

    1 trial

  14. SPD489

    Takeda Pharmaceuticals International AG

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    2 trials

  15. SPD489

    Takeda Pharmaceuticals International AG

    Schizophrenia

    phase 3 small molecule terminated

    1 trial

  16. SPD489 (Lisdexamfetamine dimesylate)

    Takeda Pharmaceuticals International AG

    Major Depressive Disorder

    phase 3 small molecule completed

    2 trials

  17. SPD489 (Lisdexamfetamine dimesylate)

    Takeda Pharmaceuticals International AG

    Binge Eating Disorder

    phase 3 small molecule completed

    2 trials

  18. SPD489 (Lisdexamfetamine dimesylate) + Antidepressant

    Takeda Pharmaceuticals International AG

    Major Depressive Disorder

    phase 3 small molecule terminated

    1 trial

  19. SPD489 40mg

    Takeda Pharmaceuticals International AG

    Schizophrenia

    phase 3 small molecule terminated

    1 trial

  20. SPD489 Low-Dose

    Takeda Pharmaceuticals International AG

    Negative Symptoms of Schizophrenia

    phase 3 small molecule terminated

    1 trial

  21. SPD489 low dose range (40mg, 80mg, and 100mg)

    Takeda Pharmaceuticals International AG

    Schizophrenia

    phase 3 small molecule terminated

    1 trial

  22. SPD503 (1 mg)

    Takeda Pharmaceuticals International AG

    Attention Deficit Disorder With Hyperactivity

    phase 3 small molecule completed

    1 trial

  23. SPD503 (Guanfacine hydrochloride)

    Takeda Pharmaceuticals International AG

    ADHD

    phase 3 small molecule completed

    1 trial

  24. SPD503 (Guanfacine hydrochloride) (2 mg)

    Takeda Pharmaceuticals International AG

    Attention Deficit Disorder With Hyperactivity

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources